If you liked this article you might like

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season
Momentum Is Fading
Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views